Insulin-like growth factor II and binding proteins 1 and 3 from second trimester human amniotic fluid are associated

Daniel K Tisi1, Xu-Jing Liu, Linda J Wykes

  • 1School of Dietetics and Human Nutrition, McGill University, Montreal, Canada.

Insights

Second-trimester amniotic fluid (AF) insulin-like growth factor binding proteins (IGF BP) 1 and 3 may predict infant birth weight. Higher AF IGF BP1 correlated with lower birth weight, while AF IGF BP3 indicated higher birth weight in large-for-gestational-age infants.

Area of Science:

  • Reproductive biology
  • Endocrinology
  • Fetal development

Background:

  • Fetal growth is influenced by amniotic fluid (AF) components, including growth factors.
  • Insulin-like growth factor II (IGF II) and its binding proteins (IGF BP) are crucial for fetal development.
  • Early pregnancy markers for fetal growth are valuable for clinical assessment.

Purpose of the Study:

  • To quantify insulin-like growth factor II (IGF II) and its binding proteins (IGF BP) 1 and 3 in second-trimester amniotic fluid (AF).
  • To determine if AF IGF II, IGF BP1, and IGF BP3 concentrations predict infant birth weight and classify fetal growth (small-for-gestational-age [SGA] or large-for-gestational-age [LGA]).

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) was used to measure AF IGF II, IGF BP1, and IGF BP3.
  • Multivariate regression analysis controlled for maternal and infant variables.
  • Birth weight was categorized using standardized percentiles for SGA and LGA classification.

Main Results:

  • Higher AF IGF BP1 concentrations were associated with lower infant birth weight (partial r² = 0.0062).
  • AF IGF BP3 showed a positive association with birth weight in large-for-gestational-age (LGA) and macrosomia subpopulations (partial r² = 0.0283 and 0.0404, respectively).
  • IGF II levels were also assessed, though specific associations with birth weight categories were not detailed in the provided text.

Conclusions:

  • Second-trimester amniotic fluid IGF BP1 and IGF BP3 may serve as early predictive markers for fetal growth.
  • These findings suggest potential for non-invasive monitoring of fetal growth trajectories.
  • Further research could elucidate the precise roles of AF IGFs and IGF BPs in regulating fetal size.

Related Concept Videos

Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...